Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2

Detalhes bibliográficos
Autor(a) principal: Faísca, Francisco
Data de Publicação: 2022
Outros Autores: Correia, Vanessa, Petrovski, Željko, Branco, Luís C., Rebelo-de-Andrade, Helena, Santos, Miguel M.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/143552
Resumo: The authors also thank Fundação para a Ciência e Tecnologia for the projects Research 4 COVID-19 no. 582, and RECI/BBBBQB/0230/2012. The authors also acknowledge the Solchemar company. Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
id RCAP_35f1de7d1d9a3c525d43910045adac64
oai_identifier_str oai:run.unl.pt:10362/143552
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2API-ILsCOVID-19hydroxychloroquinepharmaceutical ionic liquidsSARS-CoV-2Pharmaceutical ScienceSDG 3 - Good Health and Well-beingThe authors also thank Fundação para a Ciência e Tecnologia for the projects Research 4 COVID-19 no. 582, and RECI/BBBBQB/0230/2012. The authors also acknowledge the Solchemar company. Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.The development of effective antiviral drugs against SARS-CoV-2 is urgently needed and a global health priority. In light of the initial data regarding the repurposing of hydroxychloroquine (HCQ) to tackle this coronavirus, herein we present a quantitative synthesis and spectroscopic and thermal characterization of seven HCQ room temperature ionic liquids (HCQ-ILs) obtained by direct protonation of the base with two equivalents of organic sulfonic, sulfuric and carboxylic acids of different polarities. Two non-toxic and hydrophilic HCQ-ILs, in particular, [HCQH2 ][C1 SO3 ]2 and [HCQH2 ][GlcCOO]2, decreased the virus-induced cytopathic effect by two-fold in comparison with the original drug, [HCQH2 ][SO4 ]. Despite there being no significant differences in viral RNA production between the three compounds, progeny virus production was significantly affected (p < 0.05) by [HCQH2 ][GlcCOO]2 . Overall, the data suggest that the in vitro antiviral activities of the HCQ-ILs are most likely the result of specific intra-and intermolecular interactions and not so much related with their hydrophilic or lipophilic character. This work paves the way for the development of future novel ionic formulations of hydroxychloroquine with enhanced physicochemical properties.DQ - Departamento de QuímicaLAQV@REQUIMTERUNFaísca, FranciscoCorreia, VanessaPetrovski, ŽeljkoBranco, Luís C.Rebelo-de-Andrade, HelenaSantos, Miguel M.2022-09-06T22:42:40Z2022-04-172022-04-17T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article21application/pdfhttp://hdl.handle.net/10362/143552eng1999-4923PURE: 46294538https://doi.org/10.3390/pharmaceutics14040877info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:21:59Zoai:run.unl.pt:10362/143552Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:51:00.646483Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2
title Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2
spellingShingle Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2
Faísca, Francisco
API-ILs
COVID-19
hydroxychloroquine
pharmaceutical ionic liquids
SARS-CoV-2
Pharmaceutical Science
SDG 3 - Good Health and Well-being
title_short Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2
title_full Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2
title_fullStr Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2
title_full_unstemmed Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2
title_sort Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2
author Faísca, Francisco
author_facet Faísca, Francisco
Correia, Vanessa
Petrovski, Željko
Branco, Luís C.
Rebelo-de-Andrade, Helena
Santos, Miguel M.
author_role author
author2 Correia, Vanessa
Petrovski, Željko
Branco, Luís C.
Rebelo-de-Andrade, Helena
Santos, Miguel M.
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv DQ - Departamento de Química
LAQV@REQUIMTE
RUN
dc.contributor.author.fl_str_mv Faísca, Francisco
Correia, Vanessa
Petrovski, Željko
Branco, Luís C.
Rebelo-de-Andrade, Helena
Santos, Miguel M.
dc.subject.por.fl_str_mv API-ILs
COVID-19
hydroxychloroquine
pharmaceutical ionic liquids
SARS-CoV-2
Pharmaceutical Science
SDG 3 - Good Health and Well-being
topic API-ILs
COVID-19
hydroxychloroquine
pharmaceutical ionic liquids
SARS-CoV-2
Pharmaceutical Science
SDG 3 - Good Health and Well-being
description The authors also thank Fundação para a Ciência e Tecnologia for the projects Research 4 COVID-19 no. 582, and RECI/BBBBQB/0230/2012. The authors also acknowledge the Solchemar company. Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
publishDate 2022
dc.date.none.fl_str_mv 2022-09-06T22:42:40Z
2022-04-17
2022-04-17T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/143552
url http://hdl.handle.net/10362/143552
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1999-4923
PURE: 46294538
https://doi.org/10.3390/pharmaceutics14040877
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 21
application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138105380306944

Registros relacionados